Literature DB >> 8026998

Nonsteroidal anti-inflammatory drug use in the elderly: issues of compliance and safety.

J T Kirchner1.   

Abstract

Many of the goals in caring for patients with non-life-threatening rheumatic conditions can be safely met with non-steroidal anti-inflammatory drug (NSAID) therapy. These drugs relieve pain and stiffness and help to maintain joint mobility. However, no course of treatment can be successful without patient compliance. The difficulties of following dosage requirements and scheduling, together with the increased risk of adverse side effects, are particular problems for the elderly--the very patients who are the major consumers of NSAIDs. The key to successful NSAID therapy is maintaining patient comfort and function while using the simplest and safest medical regimen available. The author discusses ways in which these goals can be achieved.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8026998

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  4 in total

Review 1.  Improving the gastrointestinal safety of NSAIDs: the development of misoprostol--from hypothesis to clinical practice.

Authors:  F E Silverstein
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

2.  The elderly and their medication: understanding and compliance in a family practice.

Authors:  P Blenkiron
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

3.  Web-Based Study of Risk Factors for Pain Exacerbation in Osteoarthritis of the Knee (SPARK-Web): Design and Rationale.

Authors:  Joanna Makovey; Ben Metcalf; Yuqing Zhang; Jian Sheng Chen; Kim Bennell; Lyn March; David J Hunter
Journal:  JMIR Res Protoc       Date:  2015-07-08

Review 4.  The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly.

Authors:  Leonardo Bencivenga; Klara Komici; Graziamaria Corbi; Antonio Cittadini; Nicola Ferrara; Giuseppe Rengo
Journal:  Front Physiol       Date:  2018-07-09       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.